miércoles, 22 de octubre de 2014

Drug-Resistant Candida glabrata Infection in Cancer Patients - Volume 20, Number 11—November 2014 - Emerging Infectious Disease journal - CDC

full-text ►

Drug-Resistant Candida glabrata Infection in Cancer Patients - Volume 20, Number 11—November 2014 - Emerging Infectious Disease journal - CDC

Volume 20, Number 11—November 2014


Drug-Resistant Candida glabrata Infection in Cancer Patients

Dimitrios Farmakiotis1, Jeffrey J. Tarrand, and Dimitrios P. KontoyiannisComments to Author 
Author affiliations: The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (D. Farmakiotis, J.J. Tarrand, D.P. Kontoyiannis)Baylor College of Medicine, Houston (D. Farmakiotis)


Cancer patients are at risk for candidemia, and increasing Candida spp. resistance poses an emerging threat. We determined rates of antifungal drug resistance, identified factors associated with resistance, and investigated the correlation between resistance and all-cause mortality rates among cancer patients with ≥1 C. glabrata–positive blood culture at MD Anderson Cancer Center, Houston, Texas, USA, during March 2005–September 2013. Of 146 isolates, 30 (20.5%) were resistant to fluconazole, 15 (10.3%) to caspofungin, and 10 (6.8%) to multiple drugs (9 caspofungin-resistant isolates were also resistant to fluconazole, 1 to amphotericin B). Independently associated with fluconazole resistance were azole preexposure, hematologic malignancy, and mechanical ventilation. Independently associated with caspofungin resistance were echinocandin preexposure, monocytopenia, and total parenteral nutrition. Fluconazole resistance was highly associated with caspofungin resistance, independent of prior azole or echinocandin use. Caspofungin resistance was associated with increased 28-day all-cause mortality rates. These findings highlight the need for good stewardship of antifungal drugs.
Patients with cancer are often at risk for candidemia because of indwelling catheters, abdominal surgery, use of cytotoxic chemotherapy, parenteral nutrition, antibacterial drugs, and corticosteroids (15). Increasing drug resistance among Candida spp. poses an emerging threat to these patients. Moreover, the widespread prophylactic use of azoles in patients with hematologic malignancies and a reduced threshold for empiric initiation of antifungal treatment among critically ill patients have led to a notable shift from infections with C.albicans to infections with non-albicans Candida species (24). Among cancer patients, one of the most commonCandida species isolated is C. glabrata (35), which is the main species exhibiting multiazole, echinocandin, and multidrug resistance (resistance to at least 2 classes of antifungal drugs) (69).
Recently, on the basis of the integration of epidemiologic, molecular, and limited clinical data, the Clinical Laboratory Standards Institute (CLSI) updated antifungal susceptibility break points for Candida spp. (10,11). According to the new definitions, rates of caspofungin nonsusceptibility among C. glabrata clinical isolates range from <10% (12) to as high as 62% (13). Previous use of azoles or echinocandins are strong predictors of resistance to the respective classes (3,5,6,14,15), but little is known about the current rates of cross-resistance between azoles and echinocandins in patients with cancer or about additional clinical factors that could be associated with resistance. In a contemporary cohort of cancer patients with C. glabrata fungemia, we determined rates of in vitro resistance and cross-resistance to azoles and echinocandins, identified factors associated with resistance, and investigated the association between antifungal resistance and all-cause mortality rates.

Dr Farmakiotis is board certified in internal medicine and works as a transplant infectious diseases fellow at Brigham and Women’s Hospital and Dana Farber Cancer Institute. His research interests focus on fungal infections in immunocompromised patients with cancer, particularly those with hematologic malignancies.


We thank Dong Sik Yung for his contribution to data collection, Nathaniel D. Albert for technical support, and Ying Jang for her assistance with statistical analyses.
D.P.K. is the Frances King Black Endowed Professor for Cancer Research and. has received research support and honoraria from Astellas US, Pfizer, Gilead, and Merck & Co., Inc.


  1. Pappas PGKauffman CAAndes DBenjamin DK JrCalandra TFEdwards JE JrClinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis2009;48:50335DOIPubMed
  2. Antoniadou ATorres HALewis REThornby JBodey GPTarrand JPCandidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine2003;82:30921DOIPubMed
  3. Hachem RHannah HKontoyiannis DJang YRaad IThe changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer2008;112:24939DOIPubMed
  4. Sipsas NVLewis RETarrand JHachem RRolston KVRaad IICandidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer2009;115:474552DOIPubMed
  5. Slavin MASorrell TCMarriott DThursky KANguyen QEllis DHCandidemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother2010;65:104251DOIPubMed
  6. Alexander BDJohnson MDPfeiffer CDJiménez-Ortigosa CCatania JBooker RIncreasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated MIC. Clin Infect Dis2013;56:172432DOIPubMed
  7. Rodrigues CFSilva SHenriques MCandida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis2014;33:67388.DOIPubMed
  8. Singh-Babak SDBabak TDiezmann SHill JAXie JLChen YLGlobal analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog2012;8:e1002718DOIPubMed
  9. Ostrosky-Zeichner LCandida glabrata and FKS mutations: witnessing the emergence of the true multi-drug resistant Candida. Clin Infect Dis.2013;56:17334DOIPubMed
  10. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th ed. M27–S4. Wayne (PA): The Institute; 2012.
  11. Pfaller MAAntifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med2012;125:S313DOIPubMed
  12. Fothergill AWSutton DAMcCarthy DIWiederhold NPThe impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol2014;52:9947 . DOIPubMed
  13. Wisplinghoff HEbbers JGeurtz LStefanik DMajor YEdmond MBNosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents2014;43:7881DOIPubMed
  14. Shields RKNguyen MHPress EGUpdike CLClancy CJCaspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother2013;57:352835DOIPubMed
  15. Shields RKNguyen MHPress EGUpdike CLClancy CJAnidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and echinocandin resistance. Antimicrob Agents Chemother2013;57:63615DOIPubMed
  16. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. M27–A3. Wayne (PA): The Institute; 2008.
  17. Beyda NDJohn JKilic AAlam MJLasco TMGarey KWFKS mutant Candida glabrata; risk factors and outcomes in patients with candidemia. Clin Infect Dis2014;59:81925DOIPubMed
  18. Stratman RCMartin CARapp RPBerger RMagnuson BCandidemia incidence in recipients of parenteral nutrition. Nutr Clin Pract.2010;25:2829DOIPubMed
  19. Luzzati RCavinato SGiangreco MGranà GCentonze SDeiana MLPeripheral and total parenteral nutrition as the strongest risk factors for nosocomial candidemia in elderly patients: a matched case–control study. Mycoses2013;56:66471DOIPubMed
  20. Pfaller MACastanheira MLockhart SRAhlquist AMMesser SAJones RNFrequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol2012;50:1199203DOIPubMed
  21. Pham CDIqbal NBolden CBKuykendall RJHarrison LHFarley MMThe role of FKS mutations in C. glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother2014;58:46906DOIPubMed
  22. Farmakiotis DTarrand JJKontoyiannis DP. Application of the combined CLSI/EUCAST breakpoints for azole and echinocandin susceptibilities ofCandida isolates in a tertiary cancer center: the emerging threat of multidrug resistance. In: Book of Abstracts of the 12th ASM Conference onCandida and Candidiasis; New Orleans, LA; 2014 Mar 26–30. Oral presentation S8:5, p. 60 [cited 2014 Jun 19].http://conferences.asm.org/images/2014_candida_web_program.pdf
  23. Miyazaki T. A single amino acid mutation in IPI1 confers multi-antifungal resistance without affecting virulence in Candida glabrata. In: Book of Abstracts of the 12th ASM Conference on Candida and Candidiasis; New Orleans, LA; 2014 Mar 26–30. Invited oral presentation S10C, p. 73 [cited 2014 Jun 19]. http://cofnerences.asm. org/images/2014_candida_web_program.pdf
  24. Schulz BKnobloch MWeber KRuhnke MDoxorubicin selects for fluconazole-resistant petite mutants in Candida glabrata isolates. Int J Med Microbiol2012;302:15561DOIPubMed
  25. Ben-Ami ROlshtain-Pops KKrieger MOren IBishara JDan MAntibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother2012;56:251823DOIPubMed
  26. Ben-Ami RGarcia-Effron GLewis REGamarra SLeventakos KPerlin DSFitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis2011;204:62635DOIPubMed
  27. Fernández-Silva FLackner MCapilla JMayayo ESutton DCastanheira MIn-vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. Antimicrob Agents Chemother2014;58:36469DOIPubMed
  28. Ferrari SSanguinetti MDe Bernardis FTorelli RPosteraro BVandeputte PLoss of mitochondrial functions associated with azole resistance inCandida glabrata results in enhanced virulence in mice. Antimicrob Agents Chemother2011;55:185260DOIPubMed
  29. Eschenauer GANguyen MHShoham SVazquez JAMorris AJPasculle WAReal-world experience with echinocandin MICs against Candidaspecies in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother.2014;58:1897906DOIPubMed
  30. Espinel-Ingroff AArendrup MCPfaller MABonfietti LXBustamante BCanton EInterlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother2013;57:583642.DOIPubMed
  31. Shields RKNguyen MHPress EGKwa ALCheng SDu CThe presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother2012;56:48629.DOIPubMed



Technical Appendix

Suggested citation for this article: Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis [Internet]. 2014 Nov [date cited]. http://dx.doi.org/10.3201/eid2011.140685
DOI: 10.3201/eid2011.140685
1Current affiliation: Harvard Medical School Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA

No hay comentarios:

Publicar un comentario